ArticleThe Journal of clinical investigation1991
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.
Article in The Journal of clinical investigation, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 311 citations in OpenAlex.
- Identification of Gene Signatures Differentiating Cancer from Normal Tissues Across Histological Classifications of Gastric Adenocarcinoma via Machine Learning Methods.Biochemical genetics · 2026Article
- New and emerging strategies for targeting cancers: Challenges and opportunities (Review).Oncology letters · 2026Review
- Article
- Identification of super-enhancer-based biomarkers for predicting survival and immunotherapy efficacy in colorectal cancer.Journal of Cancer · 2026Article
- Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion.Cell research · 2026Article
- Review
- Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells.iScience · 2025Article
- Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer.Frontiers in oncology · 2025Review
- Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Frontiers in cell and developmental biology · 2025Review
- Understanding and overcoming resistance to immunotherapy in genitourinary cancers.Cancer biology & therapy · 2024Review
- Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Antitumor Immune Responses in B2M-Deficient Cancers.Cancer immunology research · 2023Article
- Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.Journal for immunotherapy of cancer · 2023Article
- Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer.British journal of cancer · 2023Review
- Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.Cancers · 2022Review
- Exploring immunotherapy in colorectal cancer.Journal of hematology & oncology · 2022Review
- Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression.Nature communications · 2022Article
- Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The melanoma cell line FO-1 does not express HLA class I antigens and does not acquire them on the cell surface after incubation with IFN-gamma. Immunochemical studies showed that FO-1 cells synthesize HLA class I heavy chain, but do not synthesize beta 2-microglobulin (beta 2-mu). The latter abnormality is associated with lack of beta 2-mu mRNA which remains undetectable in FO-1 cells incubated with IFN-gamma. The defect was identified as a genetic lesion in the B2m gene, since DNA hybridization analysis detected a deletion of the first exon of the 5'-flanking region, and of a segment of the first intron of the B2m gene. HLA class I antigen expression was reconstituted on melanoma cells FO-1 after transfection with the wild-type mouse B2m gene, thereby confirming the abnormality of the endogenous B2m gene. The defect identified in FO-1 cells is distinct from that underlying the lack of HLA class I antigen expression by lymphoblastoid cells Daudi, but is remarkably similar to that causing lack of H-2 class I antigen expression by mouse lymphoblastoid cells R1 (TL-). These results suggest that genetic recombination in the 5' region of the B2m gene is a recurrent mechanism in B2m gene defects. In addition to contributing to our understanding of molecular abnormalities in HLA class I antigen expression by melanoma cells, FO-1 cells represent a useful model for analyzing the role of HLA class I antigens in the biology of melanoma cells and in their interaction with cells of the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.